CClinicalTrials.gg
CompletedNCT03488355Updated Jan 25, 2023Results posted

Modified Reporting From Indwelling Catheters

An interventional study of Modified laboratory report in Urinary Tract Infections, sponsored by Memorial University of Newfoundland. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-25.

Sponsored by Memorial University of Newfoundland · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Positive urine cultures collected from indwelling catheters from inpatients will be randomized to standard reporting or modified reporting. Physician antibiotic treatment decisions will be prospectively observed and determined to be appropriate or inappropriate. The hypothesis is that modified reporting will lead to an increase in the percentage of appropriate therapy without an increase in pyelonephritis or sepsis.

Read the detailed description

The proposed study is a randomized trial of two methods of laboratory reporting in which physicians are the main research participants. At the time of positive urine culture results, the patient will be randomized by computer generated random number placed into serially numbered sealed, opaque envelopes into two equal groups. One group will receive modified reporting, with a report that states "This POSITIVE urine culture collected from an indwelling catheter may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call the microbiology laboratory for identification and susceptibility results." The other group will receive conventional reporting of identification and susceptibility. Physicians will then have the option of calling the laboratory to receive the results or not. Complete results will be released by telephone and laboratory information system to physicians who call to request them. Physicians will be informed about the study prior to initiation, and debriefed about the study after the results have been collected.

Inclusion criteria will include consecutive positive urine cultures collected from indwelling catheters among patients admitted to acute care, that are greater than or equal to 18 years of age. Inpatients must be admitted to Health Sciences Center or St. Clare's Mercy hospitals only, in order to facilitate access to inpatient records.

Exclusion criteria will include pregnancy, antibiotic treatment at the time of collection, patients in the Intensive Care Unit and patients with blood neutrophils \<1.0 within 7 days, which will help protect immunocompromised individuals.

Investigators will review patient charts at 24 and 72 hours and 7 days after collection. After randomization and reporting, a physician investigator will assess inpatients for the true diagnosis of asymptomatic bacteriuria (AB) or urinary tract infection (UTI). Health records will be accessed including demographics, treatment decisions and outcomes (untreated UTI or pyelonephritis). Frequency of physician calls requesting complete reporting will be recorded.

The research hypothesis is that restricted reporting will reduce the rate of inappropriate treatment prescribed by physicians. Among inpatients, the expected rate of inappropriate treatment in the control group will be 50 percent, and 20 percent in the intervention group. Accepting a risk of type 1 error of five percent, and a risk of type 2 error of twenty percent, the study will recruit 72 patients. In order to account for missing data, recruitment will be increased to 100 patients. The statistical test to be used is a comparison of proportions between two groups (T test, two sided analysis). An intention to treat analysis including all patients randomized will be performed.

Physicians must remain unaware of the research project so that their treatment decisions are unbiased. However, a general notice will be sent to all physicians regarding the study design, and a debrief will be provided in which study results are presented and the option to withdraw data will be provided. This will cause physicians to feel less deceived while still not informing them of the study and thus will not change their behavior.

Physicians of discharged inpatients will be contacted at 7 days to assess for adverse events. Because recruitment will be brief, it is unlikely that physicians will have a second patient in the study.

Ethics permission will be sought from the local ethics board. Consent of patients or physicians will not be requested. In compliance with ethics requirements, participants will experience no more than minimal risk. If an adverse event occurs, the patient will be removed from the study immediately and given standard treatment. Physician consent will not be requested, as awareness of the study would bias treatment decisions.

The benefit of this study to patients includes a reduction in adverse events caused by inappropriate treatment. The risk to patients includes possible untreated UTI. The benefit to physicians includes education toward appropriate treatment of AB. The risk to physicians includes additional effort to access laboratory results for UTI.

Data collection will use a paper case report form, and entry into a password protected online database. Analysis will be performed using SPSS 20.0 (IBM). The only expense of the project will be the graduate student to collect the data, perform the analysis and write the manuscript. The manuscript will be published in a peer-reviewed journal and presented at a national conference.

02

Conditions studied

  • Urinary Tract Infections

Keywords

  • Catheter
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • consecutive positive urine cultures collected from indwelling catheters in inpatients that are greater than or equal to 18 years of age.
  • admitted to Health Sciences Center or St. Clare's Mercy hospitals only

Exclusion criteria

Exclusion Criteria:

  • pregnancy
  • antibiotic treatment at the time of collection
  • patients in the Intensive Care Unit
  • blood neutrophils count \<1.0 x 10E9/l, within 7 days of urine collection
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Modified Reporting

    Modified laboratory report

    Other: Modified laboratory report

  • No intervention
    Standard Reporting

    Standard laboratory report

Interventions

  • OtherModified laboratory report

    Report from microbiology laboratory: "This POSITIVE urine culture collected from an indwelling catheter may represent asymptomatic bacteriuria or urinary tract infection. If urinary tract infection is suspected clinically, please call the microbiology laboratory for identification and susceptibility results."

05

What researchers measure

Primary outcomes

  1. Number of Participants With Appropriate Treatment

    Untreated catheter-associated asymptomatic bacteriurias, plus treated catheter-associated urinary tract infections, divided by total patients.

    Time frame: 7 days after positive urine culture

Secondary outcomes

  1. Death

    All-cause mortality

    Time frame: 7 days

  2. Adverse Events

    Number of participants with adverse events.

    Time frame: 7 days after positive urine culture

06

Results

Posted Jan 25, 2023

Participant flow

Participant flow — Overall Study
MilestoneModified ReportingStandard Reporting
Started5446
Completed5446
Not completed00

Outcome measures

PrimaryNumber of Participants With Appropriate Treatment

Untreated catheter-associated asymptomatic bacteriurias, plus treated catheter-associated urinary tract infections, divided by total patients.

Time frame:
7 days after positive urine culture
Reported as:
Count of participants · Participants
Number of Participants With Appropriate Treatment
ParticipantsModified ReportingStandard Reporting
Number of Participants With Appropriate Treatment3123
Statistical analysis
  • Modified Reporting vs Standard Reporting · t-test, 2 sided · p = 0.45 · Risk ratio (rr): 1.15
SecondaryDeath

All-cause mortality

Time frame:
7 days
Reported as:
Count of participants · Participants
Death
ParticipantsModified ReportingStandard Reporting
Death43
SecondaryAdverse Events

Number of participants with adverse events.

Time frame:
7 days after positive urine culture
Reported as:
Count of participants · Participants
Adverse Events
ParticipantsModified ReportingStandard Reporting
Adverse Events1319

Adverse events

Collected over Seven days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Modified Reporting4/54 (7.4%)3/54 (5.6%)13/54 (24.1%)
Standard Reporting3/46 (6.5%)0/46 (0%)19/46 (41.3%)
Most frequent serious events
Most frequent serious events
EventModified ReportingStandard Reporting
BacteremiaInfections and infestations3/540/46
Most frequent other events
Showing 10 of 27
Most frequent other events
EventModified ReportingStandard Reporting
ConfusionNervous system disorders1/542/46
ConstipationGastrointestinal disorders0/542/46
AspirationRespiratory, thoracic and mediastinal disorders0/541/46
AnxietyPsychiatric disorders0/541/46
Auditory HallucinationsPsychiatric disorders0/541/46
CandidemiaInfections and infestations0/541/46
Decreased level of consciousnessNervous system disorders0/541/46
Decreased white blood cell countBlood and lymphatic system disorders0/541/46
DizzinessNervous system disorders0/541/46
EdemaGeneral disorders0/541/46

Baseline characteristics

Age, Continuous
Age, Continuous(years)Modified ReportingStandard ReportingTotal
Mean70.8 ± 12.673.3 ± 13.772.0 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)Modified ReportingStandard ReportingTotal
Female281846
Male262854
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Modified ReportingStandard ReportingTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Modified ReportingStandard ReportingTotal
Canada5446100
07

Study locations

1 site
  • Health Sciences Center
    Saint John's, Newfoundland and Labrador A1B3V6, Canada
08

References and documents

Publications

  • Pratt CL, Rehan Z, Xing L, Gilbert L, Fillier B, Barrett B, Daley P. Modified reporting of positive urine cultures to reduce inappropriate antibiotic treatment of catheter-associated asymptomatic bacteriuria (CA-ASB) among inpatients, a randomized controlled trial. Infect Control Hosp Epidemiol. 2021 Oct;42(10):1221-1227. doi: 10.1017/ice.2020.1397. Epub 2021 Jun 4. PubMed 34085614 ↗

Study documents

  • Protocol and statistical analysis plan · Nov 5, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03488355
Lead sponsor
Memorial University of Newfoundland
Responsible party
Peter Daley (Associate Professor, Memorial University of Newfoundland) — Principal investigator
First posted
Apr 5, 2018
Start date
Nov 5, 2018
Primary completion
Jul 31, 2019
Completion
Jul 31, 2019
Results posted
Jan 25, 2023
Last update
Jan 25, 2023

Study contacts

Brendan Barrett, MD
principal investigator · Memorial University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion